Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Characterising the T cell responses to SARS-CoV-2 including variants of concern induced by natural infection and vaccines

Adele S., (2025)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), JCI Insight, 7

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.

McLean ARD. et al, (2022)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.

Payne RP. et al, (2021), Cell, 184, 5699 - 5714.e11

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nature communications, 12

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nat Commun, 12

Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021)